Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-09-2009 | Original Article

In vitro characterization of ¹⁷⁷Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study

Authors: Flavio Forrer, Jianhua Chen, Melpomeni Fani, Pia Powell, Andreas Lohri, Jan Müller-Brand, Gerhard Moldenhauer, Helmut R. Maecke

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2009

Abstract

Purpose

¹³¹I- and ⁹⁰Y-labelled anti-CD20 antibodies have been shown to be effective in the treatment of low-grade, B-cell non-Hodgkin’s lymphoma (NHL). However, the most appropriate radionuclide in terms of high efficiency and low toxicity has not yet been established. In this study we evaluated an immunoconjugate formed by the anti-CD20 antibody rituximab and the chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid). DOTA-rituximab was prepared as a kit formulation and can be labelled in a short time (<20 min) with either ¹⁷⁷Lu or ⁹⁰Y.

Materials and methods

Immunoconjugates with different numbers of DOTA molecules per rituximab were prepared using p-SCN-Bz-DOTA. In vitro immunoreactivity and stability were tested and preliminary dosimetric results were acquired in two patients.

Results

The immunological binding properties of DOTA-rituximab to the CD20 antigen were found to be retained after conjugation with up to four chelators. The labelled product was stable against a 10⁵ times excess of diethylenetriaminepentaacetic acid (DTPA, 37°C, 7 days). Two patients with relapsed NHL were treated with 740 MBq/m² body surface ¹⁷⁷Lu-DOTA-rituximab. Scintigraphic images showed specific uptake at tumour sites and acceptable dosimetric results. The mean whole-body dose was found to be 314 mGy. The administration of ¹⁷⁷Lu-DOTA-rituximab was tolerated well.

Conclusion

Our results show that DOTA-rituximab (4:1) can be labelled with ¹⁷⁷Lu with sufficient stability while the immunoconjugate retains its immunoreactivity. ¹⁷⁷Lu-DOTA-rituximab is an interesting, well-tolerated radiolabelled antibody with clinical activity in a low dose range, and provides an approach to the efficient treatment with few side effects for patients with relapsed NHL.

Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003;63:803–43. doi:10.2165/00003495-200363080-00005.PubMedCrossRef

Johnson TA, Press OW. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience. Ann Hematol 2000;79:175–82. doi:10.1007/s002770050576.PubMedCrossRef

Kaminski M, Estes J, Zasadny K, Francis IR, Ross CW, Tuck M, et al. Radioimmunotherapy with iodine ¹³¹I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259–66.PubMed

Maloney D, Smith B, Appelbaum F. The antitumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines (abstract). Blood 1996;88:637a.

Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005;23:7565–73. doi:10.1200/JCO.2004.00.9217.PubMedCrossRef

Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol 2003;21:1263–70. doi:10.1200/JCO.2003.08.043.PubMedCrossRef

Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143–9. doi:10.1200/JCO.2006.05.8198.PubMedCrossRef

Murray JL. Monoclonal antibody treatment of solid tumors: a coming of age. Semin Oncol 2000;27:64–70; discussion 92–100.PubMed

Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974–81.PubMed

10.

Cheson BD. Some like it hot! J Clin Oncol 2001;19:3908–11.PubMed

11.

Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. ¹³¹I-Tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441–9. doi:10.1056/NEJMoa041511.PubMedCrossRef

12.

Wiseman GA, White CA, Stabin M, Dunn WL, Erwin WD, Dahlbom M, et al. Phase I/II ⁹⁰Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000;27:766–77. doi:10.1007/s002590000276.PubMedCrossRef

13.

Wiseman GA, White CA, Witzig TE, Gordon LI, Emmanouilides C, Raubitschek A, et al. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a ⁹⁰Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res 1999;5:3281s–3286s.PubMed

14.

Roselli M, Schlom J, Gansow OA, Raubitschek A, Mirzadeh S, Brechbiel MW, et al. Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts. J Nucl Med 1989;30:672–82.PubMed

15.

Wahl RL, Wissing J, del Rosario R, Zasadny KR. Inhibition of autoradiolysis of radiolabeled monoclonal antibodies by cryopreservation. J Nucl Med 1990;31:84–9.PubMed

16.

Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72:77–89. doi:10.1016/0022-1759(84)90435-6.PubMedCrossRef

17.

Stabin MG, Brill AB. Monoclonal antibodies in the treatment of hematologic malignancies: radiation dosimetry aspects. Curr Pharm Biotechnol 2001;2:351–6. doi:10.2174/1389201013378572.PubMedCrossRef

18.

Scheidhauer K, Wolf I, Baumgartl HJ, Von Schilling C, Schmidt B, Reidel G, et al. Biodistribution and kinetics of ¹³¹I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2002;29:1276–82. doi:10.1007/s00259-002-0820-7.PubMedCrossRef

19.

Bernhardt P, Forssell-Aronsson E, Jacobsson L, Skarnemark G. Low-energy electron emitters for targeted radiotherapy of small tumours. Acta Oncol 2001;40:602–8. doi:10.1080/028418601750444141.PubMedCrossRef

20.

Bernhardt P, Benjegard SA, Kolby L, Johanson V, Nilsson O, Ahlman H, et al. Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors. Int J Radiat Oncol Biol Phys 2001;51:514–24. doi:10.1016/S0360-3016(01)01663-7.PubMed

21.

Song H, Du Y, Sgouros G, Prideaux A, Frey E, Wahl RL. Therapeutic potential of 90Y- and ¹³¹I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis. J Nucl Med 2007;48:150–7.PubMed

22.

Wiseman GA, Leigh B, Erwin WD, Lamonica D, Kornmehl E, Spies SM, et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 2002;94:1349–57. doi:10.1002/cncr.10305.PubMedCrossRef

23.

Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, et al. Radiation dosimetry results and safety correlations from ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003;44:465–74.PubMed

Title: In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study
Authors: Flavio Forrer
Jianhua Chen
Melpomeni Fani
Pia Powell
Andreas Lohri
Jan Müller-Brand
Gerhard Moldenhauer
Helmut R. Maecke
Publication date: 01-09-2009
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-009-1120-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

In vitro characterization of ¹⁷⁷Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study

Abstract

Purpose

Materials and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2009

Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma

Focal fat mimicking multiple hepatic metastases on FDG PET/CT imaging

Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: Comparison with integrated FDG PET/non-contrast-enhanced CT and enhanced CT

The influence of Bz-DOTA and CHX-A″-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114mIn-mediated targeting therapy

Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with 64Cu-DOTA-trastuzumab

99Mo supply—the times they are a-changing